Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb;15(2):173-184.
doi: 10.11909/j.issn.1671-5411.2018.02.007.

Treatment of coronary in-stent restenosis: a systematic review

Leos Pleva  1 , Pavel Kukla  1 , Ota Hlinomaz  2   3
Affiliations
Review

Treatment of coronary in-stent restenosis: a systematic review

Leos Pleva et al. J Geriatr Cardiol. 2018 Feb.

Abstract

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.

Keywords: Drug-eluting balloon; Drug-eluting stent; In-stent restenosis.

PubMed Disclaimer

References

    1. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther. 2011;29:190–198. - PubMed
    1. Scott NA. Restenosis following implantation of bare metal coronary stents: Pathophysiology and pathways involved in the vascular response to injury. Adv Drug Deliv Rev. 2006;58:358–376. - PubMed
    1. Byrne RA, Joner M, Massberg S, et al. Restenosis in bare metal and drug-eluting stents. In: Escaned J, Serruys PW, editors. Coronary stenosis, imaging, structure and physiology. 1st Edition. Toulouse, France: Europa Edition; 2010. pp. 475–496.
    1. Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis classification and implications for long-term outcome. Circulation. 1999;100:1872–1878. - PubMed
    1. Farooq V, Räber L, Gogas BD, et al. In-stent restenosis. In: Eeckhout E, Serruys PW, Wijns W, et al., editors. Percutaneous interventional cardiovascular medicine, the PCR-EAPCI textbook. 1st Edition. Toulouse, France: Europa Edition; 2012. pp. 785–826.

LinkOut - more resources